K40b

Moberg Pharma AB · Phase 2 active Small molecule

At a glance

Generic name	K40b
Sponsor	Moberg Pharma AB
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

K40b CI brief — competitive landscape report
K40b updates RSS · CI watch RSS
Moberg Pharma AB portfolio CI